Newly discovered neutralizing antibodies that target sites on the envelope proteins of HIV-1 provide a window on how some of the most powerful of these antibodies acquire their potency and breadth of activity. See Letter p.466
References
Pantophlet, R. & Burton, D. R. Annu. Rev. Immunol. 24, 739–769 (2006).
Walker, L. M. et al. Nature 477, 466–470 10.1038/nature10373 (2011).
Scheid, J. F. et al. Science 333, 1633–1637 (2011).
Wu, X. et al. Science 333, 1593–1602 (2011).
Muster, T. et al. J. Virol. 67, 6642–6647 (1993).
Buchacher, A. et al. AIDS Res. Hum. Retroviruses 10, 359–369 (1994).
Barbas, C. F. III et al. Proc. Natl Acad. Sci. USA 91, 3809–3813 (1994).
Corti, D. et al. PLoS ONE 5, e8805 (2010).
Wu, X. et al. Science 329, 856–861 (2010).
Walker, L. M. et al. Science 326, 285–289 (2009).
Bonsignori, M. et al. J. Virol. 85, 9998–10009; 10.1128/JVI.05045-11 (2011).
Scheid, J. F. et al. Nature 458, 636–640 (2009).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Clapham, P., Lu, S. Precisely tuned antibodies nab HIV. Nature 477, 416–417 (2011). https://doi.org/10.1038/477416a
Published:
Issue Date:
DOI: https://doi.org/10.1038/477416a
- Springer Nature Limited
This article is cited by
-
Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions
Scientific Reports (2017)
-
Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site
Retrovirology (2014)
-
Using convalescent whole blood or plasma as passive immune therapy for the global war against Ebola
Emerging Microbes & Infections (2014)
-
Development of prophylactic vaccines against HIV-1
Retrovirology (2013)
-
The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies
Retrovirology (2012)